Stada Generics Takes A Hit Even As Firm Steals A March On Rivals
Group’s Sales ‘Better Than The Average For The Top-Five Suppliers’
Stada saw a small drop in both sales and profitability for its Generics division, but insisted the firm’s “strong position in generics,” alongside its leading position in consumer healthcare and growing specialty offering, “put the group on a sustainable growth course.”
